Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States.
Phillip A
PA
Scott
Robert
R
Silbergleit
D002545:Brain Ischemia / Q000150:complications*; D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006801:Humans; D007275:Injections, Intravenous; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000191:economics* / Q000627:therapeutic use; D014481:United States
D010959:Tissue Plasminogen Activator